Tirzepatide GLP-2 Vial
← All Tirzepatide GLP-2 research
Tirzepatide (CAS 2023788-19-2) is a synthetic, once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been the subject of multiple large-scale, peer-reviewed randomized controlled trials published in The New England Journal of Medicine, including investigations of body weight, glycemic control, and cardiovascular outcomes in adult human participants.
Research goals: Metabolic & Weight
Description
Tirzepatide (CAS 2023788-19-2) is a synthetic, once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been the subject of multiple large-scale, peer-reviewed randomized controlled trials published in The New England Journal of Medicine, including investigations of body weight, glycemic control, and cardiovascular outcomes in adult human participants.
In the 72-week SURMOUNT-1 trial, adults receiving once-weekly subcutaneous tirzepatide achieved mean body weight reductions ranging from 15.0% (5 mg amount) to 20.9% (15 mg amount), compared with 3.1% in the placebo group [1].
Published Research on Tirzepatide
The following peer-reviewed studies are summarized below. Full citations and direct links to each publication appear in the References section. All studies described in this section were conducted in adult human participants.
SURMOUNT-1 Trial — Jastreboff et al., New England Journal of Medicine (2022)
Jastreboff and colleagues conducted the SURMOUNT-1 trial: a 72-week, double-blind, randomized, placebo-controlled phase 3 trial. The trial enrolled 2,539 adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related complication, excluding individuals with type 2 diabetes. Participants were randomized to receive once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, alongside lifestyle intervention.
The authors reported that tirzepatide produced substantial and sustained reductions in body weight
at all three amounts [1]. Mean percentage changes in body weight at week 72 were −15.0%, −19.5%, and −20.9% for the 5 mg, 10 mg, and 15 mg amounts respectively, compared with −3.1% in the placebo arm. Approximately 91% of participants in the 15 mg arm achieved at least 5% weight reduction, and 57% achieved at least 20%.
Read the full study: Tirzepatide Once Weekly for the Treatment of Obesity (NEJM 2022).
SURPASS-2 Trial — Frías et al., New England Journal of Medicine (2021)
Frías and colleagues conducted the SURPASS-2 trial: a 40-week, open-label, randomized, parallel-group, phase 3 head-to-head comparison of tirzepatide and semaglutide in adults with type 2 diabetes. The trial randomized 1,879 patients (1:1:1:1) to once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or once-weekly semaglutide at 1 mg, all as add-on therapy to metformin. Mean baseline HbA1c was 8.28% and mean baseline body weight was 93.7 kg.
The authors concluded that tirzepatide was noninferior and superior to semaglutide
with respect to mean change in glycated hemoglobin from baseline at week 40 [2]. Mean reductions in body weight were 7.6 kg, 9.3 kg, and 11.2 kg for the 5 mg, 10 mg, and 15 mg tirzepatide amounts respectively, compared with 5.7 kg for semaglutide 1 mg.
Read the full study: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (NEJM 2021).
SURPASS-CVOT Trial — Nicholls et al., New England Journal of Medicine (2025)
Nicholls and colleagues conducted the SURPASS-CVOT trial: a randomized, double-blind, active-comparator, noninferiority phase 3 trial conducted at 640 sites globally. The trial enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, comparing once-weekly tirzepatide with once-weekly dulaglutide (a GLP-1 receptor agonist with prior cardiovascular benefit established in earlier outcomes trials) over a mean follow-up of approximately four years.
The authors reported that tirzepatide was noninferior to dulaglutide
with respect to the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (12.2% vs. 13.1%; HR 0.92; P = 0.003 for noninferiority) [3]. The investigators also observed greater reductions in HbA1c, body weight, and a 16% relative reduction in all-cause mortality compared with the dulaglutide group.
Read the full study: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (NEJM 2025).
SURMOUNT-1 Three-Year Extension — Jastreboff et al., New England Journal of Medicine (2025)
In a longer-term analysis of the original SURMOUNT-1 cohort, Jastreboff and colleagues reported three-year safety and efficacy outcomes for tirzepatide in adults with both obesity and prediabetes. Participants continued once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo, with body weight and progression to type 2 diabetes assessed over 176 weeks.
The authors concluded that three years of treatment resulted in sustained weight reduction and a markedly lower risk of progression to type 2 diabetes
compared with placebo [4]. Among participants with obesity and prediabetes at baseline, the cumulative incidence of progression to type 2 diabetes was substantially lower in all tirzepatide arms than in the placebo arm.
Read the full study: Tirzepatide for Obesity Treatment and Diabetes Prevention (NEJM 2025).
About the Compound
Tirzepatide is a synthetic, 39-amino-acid linear peptide that functions as a dual agonist at two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The molecule is structurally based on the native GIP backbone, with substitutions and modifications that confer cross-reactivity with the GLP-1 receptor while resisting enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). A C-20 fatty diacid moiety is attached via a γ-glutamic acid and 2x[2-(2-aminoethoxy)ethoxy]acetic acid (AEEA) linker, enabling reversible binding to serum albumin and producing a circulatory half-life of approximately five days. This pharmacokinetic profile supports once-weekly administration in research models.
- CAS Number: 2023788-19-2
- Molecular Formula: C225H348N48O68
- Molecular Weight: 4813.45 g/mol
- Synonyms: LY3298176, GIP/GLP-1 dual agonist
- Receptor targets (in research literature): GIP receptor and GLP-1 receptor (dual agonist)
Product Specifications
Omnix Peptides supplies tirzepatide as a sterile, lyophilized (freeze-dried) powder in a sealed glass vial intended exclusively for in vitro laboratory research. Each production lot is independently characterized using high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC–MS) protocols.
- Regulatory status (as of publication): FDA-approved as Mounjaro® (May 2022) for type 2 diabetes and as Zepbound® (November 2023) for chronic weight management; EMA-approved in equivalent indications.
- Format: Lyophilized powder
- Available strengths: 5 mg · 10 mg per vial
- Verified Purity: >99% (HPLC, LC–MS)
- Container: Sterile, sealed glass vial
- Documentation: Batch-specific Certificate of Analysis (COA) available
Storage, handling, intended-use, and regulatory information are provided in the corresponding tabs on this product page.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
- Nicholls SJ, Pavo I, Bhatt DL, et al; SURPASS-CVOT Investigators. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928
- Jastreboff AM, le Roux CW, Stefanski A, et al; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819
Preparation and storage
Research-only handling information. Tirzepatide GLP-2 is sold strictly for in vitro laboratory research. The handling and storage guidance below reflects standard practice in published peptide research literature. Tirzepatide GLP-2 is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications.
Format
- Form: Vial
- Available strengths: 5mg · 10mg
- Verified purity: >99% (HPLC, LC–MS)
- Documentation: Batch-specific Certificate of Analysis (COA) included
Reconstitution for Research Use
Tirzepatide GLP-2 is supplied as a sterile, lyophilized powder. Reconstitution with bacteriostatic water (BAC water) is the standard preparation step used in published research protocols. The volume of BAC water used determines the final concentration of the reconstituted solution.
Example (for a 5mg vial reconstituted in 2 mL of BAC water):
- Total peptide: 5mg
- BAC water added: 2 mL
- Resulting concentration: ~2.5 mg/mL
Recommended practice:
- Use sterile bacteriostatic water (0.9% benzyl alcohol) for reconstitution; this preserves the solution for multi-week handling in laboratory settings.
- Allow the lyophilized powder to reach room temperature before opening the vial.
- Inject the BAC water against the inside wall of the vial — do not aim the stream directly at the lyophilized cake.
- Gently swirl the vial until the powder is fully dissolved. Do not shake.
- Once reconstituted, store the vial under refrigeration at 4 °C (39 °F).
Storage & Handling
- Upon receipt: Keep peptides cold and away from light.
- Lyophilized (unreconstituted): Stable at room temperature for several weeks; refrigeration at 4 °C (39 °F) is acceptable for short-term storage (days to weeks).
- Long-term storage (months to years): Freeze the lyophilized vial at −80 °C (−112 °F). Freezing optimally preserves peptide stability for extended periods.
- Reconstituted solution: Refrigerate at 4 °C (39 °F). Avoid freeze/thaw cycles, which can degrade peptide structure.
- Light exposure: Minimize exposure to direct light during handling; light can accelerate peptide degradation.
- Heat exposure: Do not leave the vial at room temperature longer than necessary for handling.
Important Notice
All Omnix Peptides products are sold for laboratory, research, or analytical purposes only. They are not for human consumption, veterinary use, or medical applications. Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds.
Citations
Citations and reference data. Omnix Peptides supplies research-grade compounds for use by qualified laboratory professionals. The references below cite published preclinical research conducted in animal models and in vitro systems. They are not intended to represent clinical evidence in humans, and Tirzepatide GLP-2 has not been approved by the FDA, EMA, or any other regulatory authority for any indication.
Compound Reference Data
- Compound: Tirzepatide GLP-2
- CAS Number: 2023788-19-2
- Molecular Formula: C225H348N48O68
- Molecular Weight: 4813.45 g/mol
- Sequence: —
- Synonyms: LY3298176, GIP/GLP-1 dual agonist
Selected Published Studies
The following peer-reviewed studies were conducted using animal models or in vitro cell-culture systems. They are listed here as a reference for researchers investigating Tirzepatide GLP-2. None of these studies should be interpreted as recommending Tirzepatide GLP-2 for human use, treatment, or any clinical purpose.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
- Nicholls SJ, Pavo I, Bhatt DL, et al; SURPASS-CVOT Investigators. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928
- Jastreboff AM, le Roux CW, Stefanski A, et al; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819
Evidence-Base Disclosure
The published evidence base for Tirzepatide GLP-2 consists predominantly of preclinical research — animal models (often rats or mice) and in vitro cell-culture experiments. Where Phase I or Phase II human trials exist, they are noted in the compound page summary. Researchers should interpret the cited literature within the experimental context of each individual study.
Frequently asked questions
Frequently asked questions about the Tirzepatide GLP-2 Vial. Questions on this page cover handling, storage, documentation, and ordering. Tirzepatide GLP-2 is sold for laboratory, research, or analytical purposes only — not for human consumption, veterinary use, or medical applications.
How is the Tirzepatide GLP-2 Vial prepared for laboratory research?
The Tirzepatide GLP-2 Vial is supplied as a sterile, lyophilized (freeze-dried) powder. The standard preparation step described in published peptide research literature is reconstitution with bacteriostatic water (BAC water). The volume of BAC water used determines the final concentration of the solution. See the Amount & Handling tab for a worked reconstitution example.
Why is Tirzepatide GLP-2 supplied as a lyophilized powder rather than a pre-mixed solution?
Lyophilization (freeze-drying) is the standard format for research-grade peptides because it maximizes long-term stability. A lyophilized vial stored cold and away from light remains stable for substantially longer than a pre-mixed solution. Reconstitution by the researcher also allows control over the final solution concentration.
Can the reconstituted Tirzepatide GLP-2 solution be frozen?
Freeze/thaw cycles can degrade peptide structure and should generally be avoided. Reconstituted Tirzepatide GLP-2 should be stored under refrigeration at 4 °C (39 °F) and used within the active research timeframe described in the Amount & Handling tab. For long-term storage, keep the vial lyophilized and freeze at −80 °C (−112 °F) until use.
Is Tirzepatide GLP-2 approved by the FDA?
No. Tirzepatide GLP-2 is not approved by the FDA, EMA, or any other regulatory authority for any indication. Tirzepatide GLP-2 is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes. It is not for human consumption, veterinary use, or medical applications.
What is included with each Tirzepatide GLP-2 Vial?
Each order includes the sealed product container and a batch-specific Certificate of Analysis (COA) verifying identity and purity by HPLC and LC–MS. The full COA library for Omnix Peptides is available at /coa-lab-reports/.
What is a Certificate of Analysis (COA), and how do I read it?
A COA is a batch-specific lab report that documents the identity, purity, and quality control results for the production lot you receive. The COA lists the compound name, CAS number, lot number, analytical methods used (HPLC, LC–MS), and the measured purity percentage. Every Omnix order includes the COA for the lot shipped.
What is the CAS number for Tirzepatide GLP-2?
The CAS number for Tirzepatide GLP-2 is 2023788-19-2. Researchers can use this identifier to locate published literature in PubMed and other scientific databases.
How does Omnix Peptides ship orders?
Orders ship from a US-based facility with tracked domestic shipping. Free shipping is offered on orders over $99. Lyophilized vials and capsules ship at ambient temperature; sprays ship insulated when seasonal conditions require it. Tracking information is provided by email after the order ships.
What if my product arrives damaged or the seal is broken?
Contact Omnix Peptides within 48 hours of delivery. Product damaged in transit or arriving with a compromised seal will be replaced at no cost. See the Shipping & Return Policy at /shipping-return-policy/ for full terms.
Where can I find published research on Tirzepatide GLP-2?
Peer-reviewed studies relevant to Tirzepatide GLP-2 are listed in the Citations tab on this product page. The same studies can be located independently on PubMed using the CAS number (2023788-19-2) or the compound name.
Customer reviews
Certificate of Analysis
Third-party HPLC purity analysis performed by an independent laboratory for this batch.
Reviews
There are no reviews yet.